{"title": "Clinical Trials - VBI Vaccines", "author": null, "url": "https://www.vbivaccines.com/our-pipeline/clinical-trials/", "hostname": "vbivaccines.com", "description": null, "sitename": "VBI Vaccines Inc.", "date": "2023-02-21", "cleaned_text": "From Science to the Clinic - and Beyond Our team works hard to drive our innovative pipeline programs into and through clinical development to assess the safety, tolerability, and immunogenicity of each candidate. We are grateful for the many volunteers and medical experts who participate in our studies, without whom we could not reach our goal of better health for all. [Hepatitis B](#) Prophylactic Hepatitis B Program Phase 3 : PROTECT A double-blind randomized controlled trial designed to establish the non-inferiority of a 3-antigen prophylactic hepatitis B vaccine candidate compared to Engerix-B\u00ae in adults 18 years old and the superiority of a 3-antigen prophylactic hepatitis B vaccine candidate compared to Engerix-B\u00ae in 45 years old. Status: Completed [Learn More](https://clinicaltrials.gov/ct2/show/NCT03393754?term=PROTECT+Sci-B-Vac&draw=2&rank=1) Phase 3 : CONSTANT A double-blind randomized controlled trial to assess the lot-to-lot consistency of a 3-antigen prophylactic hepatitis B vaccine candidate in adults. Status: Completed [Learn More](https://clinicaltrials.gov/ct2/show/NCT03408730?term=CONSTANT%2C+Sci-B-Vac&draw=2&rank=1) Immunotherapeutic Candidate : VBI-2601 Phase 1b/2a Study to evaluate the safety, tolerability, and antiviral activity of VBI-2601 (BRII-179) as a component of a functional cure for chronic HBV infection, developed in partnership with Brii Biosciences. Status: Completed [Learn More](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619001210167) Phase 2 Study designed to evaluate the safety and efficacy of VBI-2601 (BRII-179) in combination with an HBV-targeting siRNA (VIR-2218) in adults with chronic HBV infection. Status: Active, Not Recruiting [Learn More](https://clinicaltrials.gov/ct2/show/NCT04749368) Phase 2a/2b Study designed to evaluate the clinical effect of adding VBI-2601 (BRII-179) to existing standard-of-care therapy in non-cirrhotic HBV patients, developed in partnership with Biosciences. Status: Not Recruiting [Learn More](http://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml?keywords=CTR20213100) [Glioblastoma](#) Immunotherapeutic Candidate : VBI-1901 Phase 1/2a Ongoing evaluating the safety, tolerability, and optimal dose of VBI-1901 in subjects with Status: Active, Not VBI-2901, VBI-2902, 1a/1b Study to evaluate the safety, tolerability, and immunogenicity of the COVID-19 (SARS-CoV-2) vaccine candidates VBI-2902 and VBI-2905 in healthy adults. Status: Completed [Learn More](https://clinicaltrials.gov/ct2/show/NCT04773665?term=vbi&draw=2&rank=3) Phase 1 Study to evaluate the safety, tolerability, of multivalent coronavirus vaccine candidate VBI-2901 (SARS-CoV-2, SARS-CoV, MERS-CoV), which has been designed to increase the breadth of protection against COVID-19 and related coronaviruses. Status: Active, Not Recruiting [Cytomegalovirus](#) Prophylactic Vaccine Candidate : VBI-1501 Phase 1 Study to compare the safety and effectiveness of four different doses of VBI's CMV vaccine candidate in "}